Rice biotech studio secures investment from Modi Ventures, adds founder to board

fresh funding

RBL LLC has landed an investment from Houston-based Modi Ventures and named its founder, Sahir Ali (far left), to its board. Photo courtesy Rice University Biotech Launch Pad via LinkedIn

RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures.

Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors.

Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an oversubscribed round this summer.

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. William McKeon, president and CEO of the TMC, previously called the launch of RBL a “critical step forward” for Houston’s life sciences ecosystem.

“RBL is dedicated to building companies focused on pioneering and intelligent bioelectronic therapeutics,” Ali said in a LinkedIn post. “This partnership strengthens the Houston biotech ecosystem and accelerates the transition of groundbreaking lab discoveries into impactful therapies.”

Ali will join board members like managing partner Paul Wotton, Rice bioengineering professor Omid Veiseh, scientist and partner at KdT Ventures Rima Chakrabarti, Rice alum John Jaggers, CEO of Arbor Biotechnologies Devyn Smith, and veteran executive in the life sciences sector James Watson.

Ali has led transformative work and built companies across AI, cloud computing and precision medicine. Ali also serves on the board of directors of the Drug Information Association, which helps to collaborate in drug, device and diagnostics developments.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” Wotton said in the announcement. "Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”

From Your Site Articles
Sentinel BioTherapeutics is developing cytokine interleukin-2 (IL-2) capsules to fight many solid tumors. Photo via Getty Images.

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

Omid Veiseh from Rice University and Edward Ratner from the University of Houston have been named 2024 National Academy of Inventors fellows for their innovative contributions. Courtesy photos

2 Houston professors named as fellows for prestigious group of inventors

top innovators

The highest professional distinction awarded to academic inventors, the National Academy of Inventors, have elected two fellows from Rice University and the University of Houston for its 2024 class.

Edward Ratner, computer information systems lecturer in the Department of Information Science Technology at the University of Houston’s Cullen College of Engineering, and Omid Veiseh, bioengineer at Rice University and director of the Biotech Launch Pad, were two of the 170 honorees representing 39 states and 12 countries.

The 2024 class will be honored and presented their medals on June 26 in Atlanta, Georgia by a senior official of the U.S. Patent and Trademark Office.

Ratner’s research includes artificial intelligence, machine learning, image analysis, video compression and video streaming, and has led to 40 patents currently. His inventions on adaptive video streaming assists the technology used today for streaming video over the internet. Ratner becomes the 40th UH faculty who is either a fellow or senior member of the NAI.

“Ed Ratner’s recognition as a Fellow of the NAI is a testament to his exceptional creativity, dedication and impact in advancing innovation,” Ramanan Krishnamoorti, vice president of energy and innovation at UH, says in a news release. “Here at the University of Houston, we take great pride in fostering a culture where visionary thinkers like Ed can thrive. This honor reflects not only his remarkable achievements but also the University’s commitment to shaping the future through groundbreaking research and invention.”

Veiseh is a current professor of bioengineering, a Cancer Prevention and Research Institute of Texas Scholar and faculty director of the Rice Biotech Launch Pad, which is a Houston-based accelerator that focuses on “expediting the translation of the university’s health and medical technology discoveries into cures,” according to a news release from Rice.

His research focuses on developing innovative treatments that involve combining synthetic biology, molecular engineering and advanced materials science. He also helped lead a $45 million project funded by the Advanced Research Projects Agency for Health (ARPA-H) to create implantable cancer monitoring and treatment devices.

“It is our mission to make sure that scientific and technological advancements are translated from laboratory discoveries into life-saving cures and products that have a real and enduring impact on patients’ lives,” said Veiseh in a news release. “I am honored to be recognized by this distinguished award and would like to thank my collaborators at Rice and elsewhere for working toward this shared goal of improving lives through better, more effective treatments.”

In

2023, UH’s Vincent Donnelly, Moores professor of Chemical and Biomolecular Engineering, and Christine Ehlig-Economides, Hugh Roy and Lillie Cranz Cullen Distinguished university chair of Petroleum Engineering, all received the Fellows honor. Other 2024 Texas-based fellows include Malcom Brenner from Baylor College of Medicine, Maria Croyle from The University of Texas at Austin, Jaime Grunlan from Texas A&M University, and more.
Established to rapidly build companies based on Rice University's portfolio of over 100 patents, RBL LLC is a new biotech venture creation studio based in Texas Medical Center Helix Park. Photo courtesy of Rice

Rice University opens biotech venture studio in TMC

rapidly scaling

In its mission to amplify and advance biotech innovation, Rice University has announced its latest initiative — a new lab focused on bringing life-saving medical technologies to commercialization.

Established to rapidly build companies based on Rice University's portfolio of over 100 patents, RBL LLC is a new biotech venture creation studio based in Texas Medical Center Helix Park. RBL comes on the heels of establishing the Rice Biotech Launch Pad, a biotech innovation accelerator that opened last year.

Paul Wotton, executive director of the Rice Biotech Launch Pad, co-founded RBL with his colleagues Omid Veiseh, Rice professor of bioengineering and faculty director of the Rice Biotech Launch Pad; Jacob Robinson, Rice professor of electrical and computer engineering; and Dr. Rima Chakrabarti, a physician scientist and venture capital investor with KdT Ventures.

“This is a pivotal moment for Houston and beyond,” Wotton, who serves as RBL’s managing partner, says in a news release from Rice. “Houston has rapidly emerged as a global life sciences powerhouse, blending cutting-edge research with early clinical applications at Rice and the city’s world-renowned hospital systems.

"Investors from across the nation are recognizing Houston’s potential, and with RBL, we’re building on that momentum," he continues. "We’ll not only amplify the work of the Rice Biotech Launch Pad but expand our reach across Texas, creating opportunities for biotech ventures statewide and driving growth for the biotech industry as a whole.”

Strategically located in TMC, RBL will collaborate with medical leaders, investors, corporations, and other players both in the same building and on the greater TMC campus.

“Leveraging Rice University’s Biotech Launch Pad breakthroughs and pairing it with the world-class translational infrastructure of TMC Helix Park well positions RBL to drive unprecedented advances in patient care,” William McKeon, president and CEO of the TMC, says in the release. “This partnership between academia, industry and health care is exactly what’s needed to transform medical discoveries into real-world solutions that improve lives globally.”

RBL is Rice's latest effort to bridge the gap between academia and biotech innovation, an effort led by Paul Cherukuri, Rice’s chief innovation officer, who reportedly spearheaded development of the new initiative.

“RBL is a game-changer for Rice, Houston and the global biotech community,” Cherukuri adds. “This venture not only accelerates the commercialization of our innovations but also sets a blueprint for other universities looking to maximize the real-world impact of their discoveries. By combining scientific expertise with entrepreneurial support from Day Zero together with strategic clinical partnerships in the TMC, we’re creating a model for driving large-scale biotech innovation that universities everywhere should aspire to replicate.”

Since the Rice Biotech Launch Pad was established, Motif Neurotech closed its series A round with an oversubscribed $18.75 million, the hub secured a $34.9 million grant, and a “living pharmacy” founded at the Launch Pad received industry validation.

“RBL provides a powerful platform to translate high-impact scientific discoveries into therapies that will dramatically improve patient outcomes,” Veiseh says. “Our goal is to rapidly bring Rice’s pioneering research into the clinic, delivering life-saving solutions to patients around the world.”

Rice’s Biotech Launch Pad will lead the effort to commercialize the device. Photo courtesy Rice University

Rice researchers secure $35M federal grant to advance medical device technology

big money

Rice University has secured part of a nearly $35 million federal grant aimed at commercializing a bioelectric implant for treatment of type 2 diabetes and obesity.

The federal Advanced Research Projects Agency for Health awarded the $34.9 million grant to Rice and several other universities.

Rice’s Biotech Launch Pad will lead the effort to commercialize the self-contained, implantable Rx On-site Generation Using Electronics (ROGUE) device. ROGUE houses cells that are engineered to produce type 2 diabetes and obesity therapies in response to patients’ needs.

Carnegie Mellon University leads the team of researchers handling development and testing of ROGUE, which acts as a “living pharmacy” designed to make biologic drugs available on demand in a patient’s body.

The ROGUE initiative aims to keep the cost of this treatment significantly below the cost of other biologics-based treatments.

“ROGUE’s innovative design combines efficient biological manufacturing, long-term durability, and patient-friendly features that have the potential to transform the landscape of biologics delivery,” Omid Veiseh, professor of bioengineering and faculty director of the Rice Biotech Launch Pad, says in a news release.

Paul Wotton, an in-house entrepreneur at the university and executive director of the Rice accelerator, is helping guide ROGUE toward becoming an independent company.

“With the Biotech Launch Pad, our goal is venture creation in parallel to the groundbreaking research at Rice and its collaborating institutions,” Wotton says.

Omid Veiseh is professor of bioengineering and faculty director of the Rice Biotech Launch Pad. Photo courtesy Rice University

The two new awardees are LymphGuide and HEXASpec, which were selected from 26 applications. Each company received an $100,000 grant. Photo courtesy of The Ion

2 lab-stage Houston startups receive fresh funding from Rice University grant program

cashing in on innovation

Rice University has doled out another batch of grants from its program supporting lab-based innovations.

The One Small Step Grant, which was announced a year ago and gave out its first grants in February, was established to fund Rice-founded, lab-stage projects on their path to commercialization

“The One Small Step Grant invites applications from students and faculty who are tackling some of the world’s most pressing challenges and preparing to bring their innovative technologies to market,” Nafisa Istami, innovation manager at Rice, says in a news release. “We received highly competitive applications from across campus, truly showcasing the growing momentum of technology innovation happening at Rice.”

The two new awardees are LymphGuide and HEXASpec, which were selected from 26 applications. Each company received an $100,000 grant.

LymphGuide was developed by Martha Fowler in Rice professor Omid Veiseh’s lab. The hydrogel platform is a customizable alginate that's combined with an engineered cell therapy to aid in lymphatic cell regrowth, initially targeting the treatment and prevention of lymphedema.

"We are profoundly grateful to the One Small Step Grant for supporting our vision to treat lymphedema,” says Martha Fowler, cofounder of LymphGuide. “This funding will propel our biotechnology into pre-clinical evaluation to make a meaningful impact in scientific research and for people suffering from lymphatic disease.” Fowler is also an active contributor in the Rice entrepreneurship ecosystem and an Liu Idea Lab of Innovation and Entrepreneurship Innovation Fellows Cohort 2 member.

Led by by Tianshu Zhai in Rice professor Jun Lou’s lab, HEXASpec develops inorganic fillers and molding compounds for next-generation chip packaging. Zhai is also one of the Liu Idea Lab of Innovation and Entrepreneurship Innovation Fellows.

“We are thrilled to receive the One Small Step Grant from Rice Innovation,” says Tianshu Zhai, cofounder of HEXASpec. “This support is crucial for advancing HEXASpec and signifies the strong backing of the Rice entrepreneurship community. We’re grateful for the opportunity to develop our technology with such robust support.”

The next round of grant opportunities will open next month with an online application process.

“The One Small Step Grant program is a demonstration of Rice’s commitment to supporting the commercialization of Rice technologies,” says Adrian Trömel, associate vice president of Innovation Strategy and Investments. “Each cycle further highlights the impactful work of Rice students and faculty to solve global problems across industries.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Meet 6 mentors who are helping the Houston startup scene flourish

meet the finalists

Few founders launch successful startups alone — experienced and insightful mentors often play an integral role in helping the business and its founders thrive.

The Houston startup community is home to many mentors who are willing to lend an ear and share advice to help entrepreneurs meet their goals.

The Mentor of the Year category in our 2025 Houston Innovation Awards will honor an individual like this, who dedicates their time and expertise to guide and support budding entrepreneurs. The award is presented by Houston City College Northwest.

Below, meet the six finalists for the 2025 award. They support promising startups in the medical tech, digital health, clean energy and hardware sectors.

Then, join us at the Houston Innovation Awards this Thursday, Nov. 13 at Greentown Labs, when the winner will be unveiled. The event is just days away, so secure your seats now.

Anil Shetty, InformAI

Anil Shetty serves as president and chief medical officer for biotech company Ferronova and chief innovation officer for InformAI. He's mentored numerous medical device and digital health companies at seed or Series A, including Pathex, Neurostasis, Vivifi Medical and many others. He mentors through organizations like Capital Factory, TMC Biodesign, UT Venture Mentoring, UTMB Innovation and Rice's Global Medical Innovation program.

"Being a mentor means empowering early-stage innovators to shape, test, and refine their ideas with clarity and purpose," Shetty says. "I’m driven by the opportunity to help them think strategically and pivot early before resources are wasted. At this critical stage, most founders lack the financial means to bring on seasoned experts and often haven’t yet gained real-world exposure. Mentorship allows me to fill that gap, offering guidance that accelerates their learning curve and increases the chances of meaningful, sustainable impact."

Jason Ethier, EnergyTech Nexus

Jason Ethier is the founding partner of EnergyTech Nexus, through which he has mentored numerous startups and Innovation Awards finalists, including Geokiln, Energy AI Solutions, Capwell Services and Corrolytics. He founded Dynamo Micropower in 2011 and served as its president and CEO. He later co-founded Greentown Labs in Massachusetts and helped bring the accelerator to Houston.

"Being a mentor means using my experience to help founders see a clearer path to success. I’ve spent years navigating the ups and downs of building companies, struggling with cash flow, and making all the mistakes; mentoring gives me the chance to share those lessons and show entrepreneurs the shortcuts I wish I’d known earlier," Ethier says. "At Energytech Nexus, that role goes beyond just helping individual founders — it’s about creating a flywheel effect for Houston’s entire innovation ecosystem."

Jeremy Pitts, Activate Houston

Jeremy Pitts serves as managing director of Activate Houston, which launched in Houston last year. He was one of the founders of Greentown Labs in the Boston area and served in a leadership role for the organization between 2011 and 2015. Through Activate, he has mentored numerous impactful startups and Innovation Awards finalists, including Solidec, Coflux Purification, Bairitone Health, Newfound Materials, Deep Anchor Solutions and others.

"Being a mentor to me is very much about supporting the person in whatever they need. Oftentimes that means supporting the business—providing guidance and advice, feedback, introductions, etc," But just as important is recognizing the person and helping them with whatever challenges they are going through ... Sometimes they need a hype man to tell them how awesome they are and that they can go do whatever hard thing they need to do. Sometimes they just need an empathetic listener who can relate to how hard these things are. Being there for the person and supporting them on their journey is key to my mentorship style."

Joe Alapat, Liongard

Joe Alapat founded and serves as chief strategy officer at Houston software company Liongard and chief information officer at Empact IT, which he also owns. He mentors through Founder Fridays Houston Group, Software Day by Mercury Fund, SUPERGirls SHINE Foundation, Cup of Joey and at the Ion. He's worked with founders of FlowCare, STEAM OnDemand, Lokum and many other early stage startups.

"Being a mentor to me means unleashing an individual’s 10x—their purpose, their ikigai (a Japanese concept that speaks to a person’s reason for being)," Alapat says. "Mentoring founders in the Houston community of early stage, high-growth startups is an honor for me. I get to live vicariously through a founder’s vision of the future. Once they show me that compelling vision, I’m drawn to bring the future forward with them so the vision becomes reality with a sense of urgency."

Neal Dikeman, Energy Transition Ventures

Neal Dikeman serves as partner at early stage venture fund Energy Transition Ventures, executive in residence at Greentown Labs, and offices in and supports Rice Nexus at the Ion. He mentors startups, like Geokiln, personally. He also mentored Helix Earth through Greentown Labs. The company went on to win in the Smart Cities, Transportation & Sustainability contest at SXSW earlier this year. Dikeman has helped launch several successful startups himself, most recently serving on the board of directors for Resilient Power Systems, which was acquired by Eaton Corp for $150 million.

"Founders have to find their own path, and most founders need a safe space where they can discuss hard truths outside of being 'on' in sales mode with their team or board or investors, to let them be able to work on their business, not just in it," Dikeman says.

Nisha Desai, Intention

Nisha Desai serves as CEO of investment firm Intention and mentors through Greentown Labs, TEX-E, Open Minds, the Rice Alliance Clean Energy Accelerator, Avatar Innovations and The Greenhouse. She currently works with founders from Solidec, Deep Anchor Solutions, CLS Wind and several other local startups, several of which have been nominated for Innovation Awards this year. She's served a board member for Greentown Labs since 2021.

"When I first started mentoring, I viewed my role as someone who was supposed to prevent the founder from making bad decisions. Now, I see my role as a mentor as enabling the founder to develop their own decision-making capability," Desai says. "Sometimes that means giving them the space to make decisions that might be good, that might be bad, but that they can be accountable for. At the end of the day, being a mentor is like being granted a place on the founder's leadership development journey, and it's a privilege I'm grateful for."

---

The Houston Innovation Awards program is sponsored by Houston City College Northwest, Houston Powder Coaters, FLIGHT by Yuengling, and more to be announced soon. For sponsorship opportunities, please contact sales@innovationmap.com.

Rice, Houston Methodist developing soft 'sleep cap' for brain health research

Researchers and scientists at Rice University and Houston Methodist are developing a “sleep cap” that aims to protect the brain against dementia and other similar diseases by measuring and improving deep sleep.

The project is a collaboration between Rice University engineering professors Daniel Preston, Vanessa Sanchez and Behnaam Aazhang; and Houston Methodist neurologist Dr. Timea Hodics and Dr. Gavin Britz, director of the Houston Methodist Neurological Institute and chairman of the Department of Neurosurgery.

According to Rice, deep sleep is essential for clearing waste products from the brain and nightly “cleaning cycles” help remove toxic proteins. These toxic proteins, like amyloids, can accumulate during the day and are linked to Alzheimer’s disease and other neurological issues.

Aazhang, director of the Rice Neuroengineering Initiative, and his team are building a system that not only tracks the brain’s clearing process but can also stimulate it, improving natural mechanisms that protect against neurodegeneration.

Earlier proof-of-concept versions of the caps successfully demonstrated the promise of this approach; however, they were rigid and uncomfortable for sleep.

Preston and Sanchez will work to transform the design of the cap into a soft, lightweight, textile-based version to make sleep easier, while also allowing the caps to be customizable and tailored for each patient.

“One of the areas of expertise we have here at Rice is designing wearable devices from soft and flexible materials,” Preston, an assistant professor of mechanical engineering, said in a news release. “We’ve already shown this concept works in rigid device prototypes. Now we’re building a soft, breathable cap that people can comfortably wear while they sleep.”

Additionally, the research team is pursuing ways to adapt their technology to measure neuroinflammation and stimulate the brain’s natural plasticity. Neuroinflammation, or swelling in the brain, can be caused by injury, stroke, disease or lifestyle factors and is increasingly recognized as a driver of neurodegeneration, according to Rice.

“Our brain has an incredible ability to rewire itself,” Aazhang added in the release. “If we can harness that through technology, we can open new doors for treating not just dementia but also traumatic brain injury, stroke, Parkinson’s disease and more.”

The project represents Rice’s broader commitment to brain health research and its support for the Dementia Prevention Research Institute of Texas (DPRIT), which passed voter approval last week. The university also recently launched its Rice Brain Institute.

As part of the project, Houston Methodist will provide access to clinicians and patients for early trials, which include studies on patients who have suffered traumatic brain injury and stroke.

“We have entered an era in neuroscience that will result in transformational cures in diseases of the brain and spinal cord,” Britz said in the release. “DPRIT could make Texas the hub of these discoveries.”

Autonomous truck company with Houston routes goes public

on a roll

Kodiak Robotics, a provider of AI-powered autonomous vehicle technology, has gone public through a SPAC merger and has rebranded as Kodiak AI. The company operates trucking routes to and from Houston, which has served as a launchpad for the business.

Privately held Kodiak, founded in 2018, merged with a special purpose acquisition company — publicly held Ares Acquisition Corp. II — to form Kodiak AI, whose stock now trades on the Nasdaq market.

In September, Mountain View, California-based Kodiak and New York City-based Ares disclosed a $145 million PIPE (private investment in public equity) investment from institutional investors to support the business combo. Since announcing the SPAC deal, more than $220 million has been raised for the new Kodiak.

“We believe these additional investments underscore our investors’ confidence in the value proposition of Kodiak’s safe and commercially deployed autonomous technology,” Don Burnette, founder and CEO of Kodiak, said in a news release.

“We look forward to leading the advancement of the commercial trucking and public sector industries,” he added, “and delivering on the exciting value creation opportunities ahead to the benefit of customers and shareholders.”

Last December, Kodiak debuted a facility near George Bush Intercontinental/Houston Airport for loading and loading driverless trucks. Transportation and logistics company Ryder operates the “truckport” for Ryder.

The facility serves freight routes to and from Houston, Dallas and Oklahoma City. Kodiak’s trucks currently operate with or without drivers. Kodiak’s inaugural route launched in 2024 between Houston and Dallas.

One of the companies using Kodiak’s technology is Austin-based Atlas Energy Solutions, which owns and operates four driverless trucks equipped with Kodiak’s driver-as-a-service technology. The trucks pick up fracking sand from Atlas’ Dune Express, a 42-mile conveyor system that carries sand from Atlas’ mine to sites near customers’ oil wells in the Permian Basin.

Altogether, Atlas has ordered 100 trucks that will run on Kodiak’s autonomous technology in an effort to automate Atlas’ supply chain.

View All Listings